BioSpace News Archive

New York, New York--(Newsfile Corp. - January 25, 2021) - PCG Digital: Advancing health care innovation is a cornerstone of thorough public health policy.

New Service Allows Patients the Convenience and Safety of Queuing up From Anywhere, Eliminating the Need to Wait in a Physical Line Outside of the Clinic

Emmaus Life Sciences, Inc. (OTC: EMMA), a leader in the treatment of sickle cell disease, reported today its financial results for the year ended December 31, 2019 and its restated financial results for the year ended December 31, 2018.

Aerobiotix, Inc., a leading manufacturer of air treatment devices for hospitals and healthcare, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Aerocure-MD medical air purification system

The partnership is built around providing greater access to quality, affordable, compassionate health care through shared education, research and clinical integration for urban and rural populations.

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it intends to offer shares of its common stock for sale in an underwritten public offering

Zomedica Corp. (NYSE American: ZOM) (“Zomedica”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that it has signed an agreement with Miller Veterinary Supply (“Miller”) for the distribution of TRUFORMA™,

No adverse effects observed at all doses tested Using the results of this study, combined with previously compiled clinical safety data, the Company intends to commence evaluation of human equivalent doses for initiating pilot clinical efficacy studies An IND submission for Chemotherapy Induced Peripheral Neuropathy is expected in the second half of 2021

Iterum Therapeutics plc today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTIs) in patients with a quinolone non-susceptible pathogen.

Advaxis today announces its financial results for the fiscal year ended October 31, 2020 and provides a business update.